Holly R. Middlekauff, MD; Isaac Wiener, MD; Leslie A. Saxon, MD; William G. Stevenson, MD
Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-Dose Amiodarone for Atrial Fibrillation: Time for a Prospective Study?. Ann Intern Med. 1992;116:1017-1020. doi: 10.7326/0003-4819-116-12-1017
Download citation file:
Published: Ann Intern Med. 1992;116(12_Part_1):1017-1020.
▪ Because atrial fibrillation is associated with substantial morbidity, restoration of sinus rhythm is desirable. Long-term maintenance of sinus rhythm often requires chronic antiarrhythmic therapy. Class I antiarrhythmic drugs such as quinidine or propafenone maintain sinus rhythm in approximately 50% of patients at 1 year and have risks for proarrhythmia and noncardiac toxicity. Studies of low-dose amiodarone for atrial fibrillation have reported sinus rhythm maintenance in 53% to 79% of patients during a mean follow-up of 27 months. Amiodarone has a lower incidence of proarrhythmia and heart failure exacerbation compared with class I drugs. Most noncardiac side effects are dose related, and low-dose amiodarone (< 300 mg/d) is well tolerated. The time has come for a large-scale prospective evaluation of low-dose amiodarone treatment early in the course of atrial fibrillation.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only